Hirawat Samit 4
4 · Pacira BioSciences, Inc. · Filed Jan 29, 2026
Research Summary
AI-generated summary of this filing
Pacira (PCRX) Director Hirawat Samit Receives Option Award
What Happened
- Hirawat Samit, a director of Pacira BioSciences, was granted a derivative award covering 39,291 shares on 2026-01-27. The Form 4 reports an acquisition price of $0.00, indicating a stock option/award rather than an open-market purchase; no cash was paid in this filing.
Key Details
- Transaction date: 2026-01-27 (reported on Form 4 filed 2026-01-29 — timely filing).
- Transaction type: Award/Grant (derivative) of 39,291 shares; reported price $0.00.
- Shares owned after transaction: Not specified in this filing.
- Footnote: The option vests one-third on the first anniversary of the grant, then in equal monthly installments over the subsequent two years, subject to continued service.
- Filing timeliness: Filed two days after the transaction date (not marked late).
Context
- This was an option/award grant (a derivative), not an exercise or sale. Such grants are typically subject to vesting and do not represent an immediate market purchase or sale. They reflect compensation or retention incentives rather than an immediate bullish or bearish trading signal.
Insider Transaction Report
Form 4
Hirawat Samit
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-01-27+39,291→ 39,291 totalExercise: $19.85Exp: 2036-01-27→ Common Stock (39,291 underlying)
Footnotes (1)
- [F1]The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Signature
/s/ Kristen Williams, Attorney-in-Fact|2026-01-29